TrianglePhase I CB-NK-TGF-ßR2-/NR3C1- in rGBM (NCT04991870)
Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM trial for Recurrent Gliosarcoma (NCT04991870). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
Recurrent glioblastoma resists nearly everything, partly because it bathes itself in TGF-beta, which puts immune cells to sleep, and because patients' steroids quiet them further.
The idea: natural killer cells edited so that neither signal can reach them, delivered straight into the tumor.
At MD Anderson, natural killer cells from donated umbilical cord blood are expanded and gene-edited to remove two receptors: the TGF-beta receptor, and the receptor for glucocorticoid steroids. They are then injected through a small reservoir under the scalp directly into the tumor, every four weeks, up to eight. In some patients, a dose comes before planned surgery, so the removed tissue shows whether the cells arrived and survived.
Shiao-Pei Weathers leads it, from age twelve. Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.